Eptifibatide-induced profound thrombocytopaenia: a rare complication

BMJ Case Rep. 2021 Jun 14;14(6):e241594. doi: 10.1136/bcr-2021-241594.

Abstract

Drug-induced immune thrombocytopaenia (DITP) is a type of thrombocytopaenia caused by medications. It is one of the common causes of unexplained thrombocytopaenia. It is caused by the formation of autoantibodies against a particular drug and is commonly observed with medications like heparin and beta-lactam antibiotics. One of the rare causes of DITP is eptifibatide, a widely used antiplatelet agent for pretreatment in cardiac catheterisation. These patients can be asymptomatic or develop complications like skin bruising, epistaxis and even intracranial haemorrhage. We present a case of a 64-year-old man who developed eptifibatide-induced profound thrombocytopaenia leading to extensive skin bruising. He was treated with platelet transfusions followed by prompt improvement in platelet count.

Keywords: haematology (drugs and medicines); interventional cardiology; unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Eptifibatide
  • Heparin
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Count
  • Thrombocytopenia* / chemically induced

Substances

  • Platelet Aggregation Inhibitors
  • Heparin
  • Eptifibatide